Rhodanine-3-acetamide derivatives as aldose and aldehyde reductase inhibitors to treat diabetic complications: synthesis, biological evaluation, molecular docking and simulation studies

Table 1 Aldehyde and aldose reductase inhibition efficacy by 5-benzylidene rhodanine-3-acetamide derivatives 3(a–g)

Codes	R1	R2	R'	ALR1	ALR2
Codes	R1	R2	R'	IC₅₀ ± SEM (µM)/% inhibition
3a	OH	OCH₃	C₆H₅NH₂	5.38 ± 0.07	0.25 ± 0.04
3b	OH	OCH₃	C₄H₉NO	6.07 ± 0.05	19.2 ± 0.08
3c	OH	OCH₃	C₇H₇NO₃	2.38 ± 0.02	6.38 ± 0.01
3d	OH	OCH₃	C₇H₇NO₂	3.76 ± 0.09	7.36 ± 0.02
3e	OCH₃	H	C₆H₅NH₂	2.87 ± 0.01	12.71 ± 0.09
3f	OCH₃	H	C₄H₉NO	2.18 ± 0.03	0.12 ± 0.01
3g	OH	OCH₃	C₄H₉N	2.22 ± 0.04	2.42 ± 0.03
Valproic acid				57.4 ± 0.89	–
Sulindac				–	0.29 ± 0.08

ISSN: 2661-801X